One Turn
Doctors back Moderna-Merck melanoma vaccine results
Six melanoma specialists said the Moderna and Merck vaccine results are a meaningful advance for patients after surgery. The personalized mRNA vaccine cut the return of melanoma in a trial. The doctors' view contrasted with a cool reaction from investors.
Why it matters
A personalized vaccine could lower the risk of skin cancer coming back for patients after surgery.
Background
The vaccine is made for each patient based on their tumor's genetic features. It is given with Merck's immunotherapy drug.
The story so far
- Personalized mRNA vaccine cuts melanoma recurrence risk in trial
- Doctors back Moderna-Merck melanoma vaccine results
Sources
- CNBC ↗Oct 23, 1:15 PM ET
This summary was written automatically from the reporting linked above; follow the sources for the full story. How One Turn works.